Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

What You Should Know: – The Substance Abuse and Mental Health Services Administration (SAMHSA) and the Office of the National Coordinator for Health Information Technology

February 7, 2024

Canary CEO Bill Hunter talks smart knee implant progress, new heart device

Canary Medical, which worked with Zimmer Biomet to develop a “smart” knee implant, is nearing a full launch of the device. Zimmer received Food and

February 15, 2024

Imbria touts PhII success in hypertrophic cardiomyopathy, adding fuel to overall efficacy profile

Imbria Pharmaceuticals’ partial fatty acid oxidation inhibitor improved outcomes in Phase II non-obstructive hypertrophic cardiomyopathy patients, with the company noting that the asset’s efficacy could

November 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.